Tag: Prostate cancer
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC
Darolutamide improves OS in mHSPC
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel
Artificial intelligence improves prediction of long-term outcomes
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity
Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment
EAU TV: Robotic surgery and advanced prostate cancer
EAU TV: The best on prostate cancer and incontinence & andrology
Best of EAU: Updates on imaging and treatment of prostate cancer
Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC
177Lu-PSMA-617: A new class of effective therapy
VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC
Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC
Lu177 as a promising new therapy for metastatic prostate cancer
Role of prostate cancer genomics is evolving
Apalutamide prolongs progression-free survival in prostate cancer
Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer
Intrinsic tumour biology may be predictive of treatment response in prostate cancer
Final TITAN trial results favour use of apalutamide
Prostate cancer: spare radiotherapy after surgery
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer
Prostate cancer active surveillance: Better patient risk stratification and use of imaging
